All In Biotech

Drug Trial Radar · NCT07615985

Phase 1a Study Assessing Safety, Tolerability, Pharmacokinetics, and Immunogenicity of PMG1016

A Phase 1a, First-in-human, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of PMG1016 in Healthy Volunteers

Last checked: Nov 20, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

May 29, 2026

Primary completion

Nov 30, 2026

Study completion Nov 30, 2026

Sponsor

Lead sponsor
Pulmongene Ltd.Industry
Sponsor type
Industry
First posted
May 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is a first-in-human (FIH), randomized, double-blind, placebo-controlled study of PMG1016 in healthy adult participants. It aims to investigate the safety, tolerability, PK, and immunogenicity of PMG1016 administered via IV infusion. Cohort 1: Healthy participants receiving single doses of PMG1016 Dose 1 or placebo. Cohort 2: Healthy participants receiving single doses of PMG1016 Dose 2 or placebo. Cohort 3: Healthy participants receiving single doses of PMG1016 Dose 3 or placebo. Cohort 4: Healthy participants receiving single doses of PMG1016 Dose 4 or placebo.

Conditions

  • Chronic Kidney Disease

Interventions

  • PMG1016 Dose 1Drug

    Participants will be administered PMG1016 Dose 1 or Placebo in a 100mL IV infusion Volume

  • PMG1016 Dose 2Drug

    Participants will be administered PMG1016 Dose 2 or Placebo in a 100mL IV infusion Volume

  • PMG1016 Dose 3Drug

    Participants will be administered PMG1016 Dose 3 or Placebo in a 100mL IV infusion Volume

  • PMG1016 Dose 4Drug

    Participants will be administered PMG1016 Dose 4 or Placebo in a 100mL IV infusion Volume

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment-emergent adverse events (TEAEs)Time frame: Day 1 to Day 57
  2. Serious adverse events (SAEs)Time frame: From Day 1 to Day 57
  3. Number of participants with abnormal pulse rateTime frame: From Day 1 to Day 57
  4. Number of participants with abnormal blood pressureTime frame: From Day 1 to Day 57
  5. Number of participants with abnormal respiratory rateTime frame: From Day 1 to Day 57
  6. Number of participants with abnormal tympanic temperatureTime frame: From Day 1 to Day 57
  7. Number of Participants with Clinically Significant Abnormal PR IntervalTime frame: From Day 1 to Day 57
  8. Number of Participants with Clinically Significant Abnormal QRS DurationTime frame: From Day 1 to Day 57
  9. Number of Participants with Clinically Significant Abnormal QT intervalTime frame: From Day 1 to Day 57
  10. Number of Participants with Clinically Significant Abnormal RR intervalTime frame: From Day 1 to Day 57
  11. Number of Participants with Clinically Significant Valvular AbnormalitiesTime frame: Day 1 to Day 29
  12. Number of Participants with Clinically Significant Abnormal Left Ventricular Ejection FractionTime frame: Day 1 to Day 29
  13. Number of Participants with Clinically Significant Abnormal Hematology ResultsTime frame: Day 1 to Day 57
  14. Number of Participants with Clinically Significant Abnormal Clinical Chemistry ResultsTime frame: Day 1 to Day 57
  15. Number of Participants with Clinically Significant Abnormal Urinalysis ResultsTime frame: Day 1 to Day 57
  16. Number of Participants with Clinically Significant Abnormal Physical Examination FindingsTime frame: Day 1 to Day 57

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nucleus Network (Brisbane)

    Brisbane, Queensland, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.